Details for Patent: 5,612,367
✉ Email this page to a colleague
| Title: | Method of enhancing bioavailability of pharmaceutical agents |
| Abstract: | The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma. |
| Inventor(s): | Timko; Robert J. (West Chester, PA), Bradway; Randy J. (Downingtown, PA), Clements; Arlene (Turnersville, NJ) |
| Assignee: | Zeneca Limited (London, GB2) |
| Filing Date: | Jun 07, 1995 |
| Application Number: | 08/474,191 |
| Claims: | 1. A method of enhancing the bioavailability of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide upon oral administration to living mammals, said method comprising formulating a pharmaceutical composition comprising, as active ingredient, an amorphous physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide, which is substantially free of other physical forms, and has an infra-red spectrum (0.5% in KBr) having sharp peaks at 1690, 1530, 1490, 1420, 1155, 1060, 862 and 550 cm.sup.-1, in combination with polyvinylpyrrolidone. 2. A method of stabilizing an amorphous physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide, having an infra-red spectrum (0.5% in KBr) having sharp peaks at 1690, 1530, 1490, 1420, 1155, 1060, 862 and 550 cm.sup.-1, in a pharmaceutical composition for administration to living mammals, said method comprising formulating a pharmaceutical composition comprising said amorphous physical form, substantially free of other physical forms, in combination with polyvinylpyrrolidone. 3. The method of claim 1 or 2 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 4. The method of claim 1 or 2 wherein said amorphous physical form is present in an amount of from 1 to 90% by weight, based upon the total weight of the composition. 5. The method of claim 4 wherein the polyvinylpyrrolidone is present in an amount of from 1 to 20% by weight, based upon the total weight of the composition. 6. The method of claim 3 wherein the pharmaceutically acceptable carrier is selected from mannitol, lactose, sorbitol, glucose, sucrose, dextrose, fructose, xylitol, microcrystalline cellulose, powdered cellulose and hydroxypropylmethylcellulose. 7. The method of claim 1 or 2 wherein the composition further comprises a processing adjuvant selected from croscarmellose sodium, sodium starch glycolate, starch, magnesium stearate, stearic acid, talc and powdered vegetable stearine. 8. The method of claim 1 or 2 wherein the composition is in the form of a tablet. |
